Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|December 15, 2019
- Pharmaceutical Technology-12-15-2019
- Volume 2019 eBook
- Issue 3
Revision Process for Global/National Pharmacopoeias (eBook)
Author(s)J. Mark Wiggins, Joseph A. Albanese
This article describes the revision process and the resulting publication of proposed and official updates for pharmacopoeias around the world.
Advertisement
Pharmacopoeia Compliance Series
Compliance with requirements published by pharmacopoeias around the world is a legal and regulatory requirement for drug companies seeking to market products in that region. The multiple pharmacopoeias around the world are frequently revised and expanded, presenting challenges for bio/pharmaceutical companies that must monitor this activity.
This article examines the revision process of global and national pharmacopoeias, the publication schedules, and describes differences between the procedures of the various authorities.
This article is part of a series that will be published in 2019–2020.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook, December 2019
December 2019
Pages: 17–25
Citation
When referring to this article, please cite it as J.M. Wiggins and J.A. Albanese, “Revision Process for Global/National Pharmacopoeias," Pharmaceutical Technology Regulatory Sourcebook eBook (December 2019).
Articles in this issue
almost 7 years ago
Regulatory and Standard Setting Organizationsalmost 7 years ago
Resources, Guidelines, and Guidance Documentsalmost 7 years ago
Design of Experiments Gains Ground in Biopharma Developmentalmost 7 years ago
Warning Letters Signal Steps to Compliancealmost 7 years ago
Quality Risk Management Plans Create Effective Quality Systemsalmost 7 years ago
Moving from Compliance to QualityAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5